# Long Term Study With B2036-PEG

Source: https://onco.cc/trials/nct00143416/  
OnCo record `nct00143416` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pegvisomant in Pituitary tumours, run by Pfizer, completed.

## Summary

Long Term Study With B2036-PEG is a phase 3 interventional study registered as NCT00143416 by Pfizer, with 16 participants recorded, started 2004-04. Interventions recorded: Pegvisomant. Conditions recorded: Acromegaly.

Linked to the drug Pegvisomant because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00143416
- Phase: 3
- Setting: Long-Term Study of B2036-PEG in Acromegaly - Long Term Study With B2036-PEG -
- Sponsor: Pfizer
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT00143416: https://clinicaltrials.gov/study/NCT00143416

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Pegvisomant](https://onco.cc/drugs/pegvisomant/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct00143416.json